6 completed. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 2 | Completed 2 |
Follow Recurrent Rhabdomyosarcoma: new trials by email Literature Review of Recurrent Rhabdomyosarcoma trials Research Report on Recurrent Rhabdomyosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Laboratory Biomarker Analysis, Lorvotuzumab Mertansine, Pharmacological Study - Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor | Phase 2 | Completed | Children's Oncology Group | 62 | 2015-10-12 | 2022-01-13 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Adavosertib, Irinotecan Hydrochloride - Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 76 | 2014-03-28 | 2023-09-26 |
Neuroblastoma (6) · Rhabdomyosarcoma (6) · Lymphoma, Non-Hodgkin (4) · Medulloblastoma (4) · Neuroectodermal Tumors, Primitive, Peripheral (4) · Osteosarcoma (4) · Wilms Tumor (4) · Central Nervous System Neoplasms (3) · Ependymoma (3) · Glioma (3) · Hepatoblastoma (3) · Histiocytosis, Langerhans-Cell (3) · Rhabdoid Tumor (3) · Sarcoma (3) · Sarcoma, Ewing (3)
Myosarcoma (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Connective and Soft Tissue (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Muscle Tissue (6) · Neoplasms, Nerve Tissue (6) · Neoplasms, Neuroepithelial (6) · Neuroectodermal Tumors (6) · Neoplasms, Connective Tissue (5) · Neuroectodermal Tumors, Primitive (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Female Urogenital Diseases (4)
Ado-Trastuzumab Emtansine (1) · CTLA-4 Antigen (1) · Ipilimumab (1) · Irinotecan (1) · LY3023414 (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Phantoms, Imaging (1) · Specimen Handling (1) · X-Rays (1) · adavosertib (1) · lorvotuzumab mertansine (1) · palbociclib (1) · tazemetostat (1)
National Cancer Institute (NCI) (5) · Children's Oncology Group (1)
United States (6) · Puerto Rico (3) · Canada (2)
Crystal L Mackall (1) · James I Geller (1) · Kristina A Cole (1) · Rajen Mody (1) · Susan N Chi (1) · Theodore W Laetsch (1)
PMID 31401903, PMID 32192573, PMID 39298716
U10CA180886 (4), UM1CA097452 (2)